key: cord-0819012-bnm8o82q
authors: Caroppo, Francesca; Deotto, Maria Ludovica; Tartaglia, Jacopo; Belloni Fortina, Anna
title: Vitiligo worsened following the second dose of mRNA SARS‐CoV‐2 vaccine
date: 2022-03-16
journal: Dermatol Ther
DOI: 10.1111/dth.15434
sha: b35b297cff554316cc146a65ef7ac2266aa7fa19
doc_id: 819012
cord_uid: bnm8o82q

nan

The pathophysiology underlying the relationship between SARS-CoV-2 vaccination and vitiligo remains unclear, but several F I G U R E 1 Worsening of vitiligo following the second dose of mRNA SARS-CoV-2 vaccination. Clinical examination showed extended vitiligo lesions involving extremities, upper limbs, axillae, trunk, and genital area with large confluent lesions. The extent of hypopigmentation was estimated at about 70% of the patient's body surface area

Worsening of the vitiligo following the second dose of the BNT162B2 mRNA COVID-19 vaccine

Vitiligo in a COVID-19-vaccinated patient with ulcerative colitis: coincidence?

Vitiligo possibly triggered by COVID-19 vaccination

New-onset vitiligo following mRNA-1273 (Moderna) COVID-19 vaccination

Sudden onset of vitiligo after COVID-19 vaccine

A new-onset vitiligo following the inactivated COVID-19 vaccine

COVID vaccine-induced lichen planus on areas previously affected by vitiligo

Vaccination and autoimmune diseases: is prevention of adverse health effects on the horizon?

Comment on 'Vitiligo in a COVID-19-vaccinated patient with ulcerative colitis: coincidence? Type I interferons as possible link between COVID-19 vaccine and vitiligo

SARS-CoV-2 induces human plasmacytoid pre-dendritic cell diversification via UNC93B and IRAK4

Type I interferon signature in the initiation of the immune response in vitiligo